BR0008182A - Antagonistas do fator de necrose tumoral e seu uso em endometriose - Google Patents

Antagonistas do fator de necrose tumoral e seu uso em endometriose

Info

Publication number
BR0008182A
BR0008182A BR0008182-5A BR0008182A BR0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A BR 0008182 A BR0008182 A BR 0008182A
Authority
BR
Brazil
Prior art keywords
antagonists
endometriosis
necrosis factor
tumor necrosis
factor antagonists
Prior art date
Application number
BR0008182-5A
Other languages
English (en)
Inventor
Francesco Borrelli
Mauro D Antonio
Fabrizio Martelli
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0008182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0008182A publication Critical patent/BR0008182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "ANTAGONISTAS DO FATOR DE NECROSE TUMORAL E SEU USO EM ENDOMETRIOSE". Antagonistas do fator de necrose tumoral são administrados em doses terapeuticamente eficazes para tratar e/ou prevenir a endometriose. Os antagonistas desta invenção são tipicamente selecionados entre várias classes de moléculas mas de preferência são receptores de TNF solúveis. Os antagonistas são úteis para a regressão de lesões endometriais e, se combinados com outros ingredientes ativos, para melhorar distúrbios relacionados, tal como infertilidade.
BR0008182-5A 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose BR0008182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (en) 1999-01-22 1999-01-22 Tumor necrosis factor antagonists and their use in endometriosis
PCT/IB2000/000052 WO2000043031A1 (en) 1999-01-22 2000-01-19 Tumor necrosis factor antagonists and their use in endometriosis

Publications (1)

Publication Number Publication Date
BR0008182A true BR0008182A (pt) 2001-11-06

Family

ID=8237393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008182-5A BR0008182A (pt) 1999-01-22 2000-01-19 Antagonistas do fator de necrose tumoral e seu uso em endometriose

Country Status (30)

Country Link
US (2) US6663865B1 (pt)
EP (2) EP1022027A1 (pt)
JP (1) JP4601176B2 (pt)
KR (2) KR20060128056A (pt)
CN (2) CN1212152C (pt)
AR (1) AR022251A1 (pt)
AT (1) ATE242002T1 (pt)
AU (1) AU771964B2 (pt)
BG (1) BG65556B1 (pt)
BR (1) BR0008182A (pt)
CA (1) CA2356737C (pt)
CZ (1) CZ302866B6 (pt)
DE (1) DE60003152T2 (pt)
DK (1) DK1143997T3 (pt)
EA (1) EA003927B1 (pt)
EE (1) EE05543B1 (pt)
ES (1) ES2200808T3 (pt)
HK (2) HK1043059B (pt)
HU (1) HU226149B1 (pt)
IL (2) IL144413A0 (pt)
NO (1) NO328814B1 (pt)
NZ (1) NZ512585A (pt)
PL (1) PL204713B1 (pt)
PT (1) PT1143997E (pt)
SI (1) SI1143997T1 (pt)
SK (1) SK287313B6 (pt)
TR (1) TR200102107T2 (pt)
UA (1) UA78483C2 (pt)
WO (1) WO2000043031A1 (pt)
ZA (1) ZA200105263B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00549B (me) * 2001-01-29 2011-10-10 Serono Lab Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
EP1596881B1 (en) * 2003-02-07 2008-12-10 Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
JP2008501035A (ja) * 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
EP2468282A3 (en) * 2005-07-12 2012-09-12 DMI Biosciences, Inc. Methods and products for treatment of diseases
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
SG2014008171A (en) * 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US20100323991A1 (en) * 2009-06-22 2010-12-23 Dmi Acquisition Corp. Methods and products for treatment of diseases
SG10201705044YA (en) 2012-12-19 2017-07-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
ES2156859T5 (es) * 1991-03-18 2008-03-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
WO1994006476A1 (en) * 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
JP2001506982A (ja) * 1996-11-27 2001-05-29 イミュネックス・コーポレーション 一酸化窒素産生の制御法
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
EA003927B1 (ru) 2003-10-30
HUP0105103A2 (hu) 2002-04-29
DE60003152T2 (de) 2004-03-25
IL144413A0 (en) 2002-05-23
IL144413A (en) 2009-05-04
PL350002A1 (en) 2002-10-21
WO2000043031A1 (en) 2000-07-27
TR200102107T2 (tr) 2001-12-21
KR100685106B1 (ko) 2007-02-22
SK10292001A3 (sk) 2001-12-03
EE05543B1 (et) 2012-06-15
EE200100378A (et) 2002-10-15
HUP0105103A3 (en) 2004-08-30
HK1043059B (zh) 2005-11-18
CN1337883A (zh) 2002-02-27
UA78483C2 (en) 2007-04-10
BG65556B1 (bg) 2008-12-30
EA200100799A1 (ru) 2001-12-24
EP1143997B1 (en) 2003-06-04
KR20010101397A (ko) 2001-11-14
SK287313B6 (sk) 2010-06-07
HK1082690A1 (en) 2006-06-16
ATE242002T1 (de) 2003-06-15
PL204713B1 (pl) 2010-02-26
PT1143997E (pt) 2003-10-31
CN1698894A (zh) 2005-11-23
CZ20012656A3 (cs) 2002-02-13
BG105691A (en) 2002-02-28
CZ302866B6 (cs) 2011-12-21
NZ512585A (en) 2003-08-29
DE60003152D1 (de) 2003-07-10
KR20060128056A (ko) 2006-12-13
HU226149B1 (en) 2008-05-28
AU771964B2 (en) 2004-04-08
AU1997300A (en) 2000-08-07
JP4601176B2 (ja) 2010-12-22
NO328814B1 (no) 2010-05-18
NO20013577D0 (no) 2001-07-19
US6663865B1 (en) 2003-12-16
SI1143997T1 (en) 2003-12-31
NO20013577L (no) 2001-08-29
CN100594932C (zh) 2010-03-24
ES2200808T3 (es) 2004-03-16
HK1043059A1 (en) 2002-09-06
CA2356737C (en) 2010-03-23
EP1022027A1 (en) 2000-07-26
DK1143997T3 (da) 2003-09-15
EP1143997A1 (en) 2001-10-17
ZA200105263B (en) 2002-06-26
JP2002535284A (ja) 2002-10-22
CN1212152C (zh) 2005-07-27
US20040057954A1 (en) 2004-03-25
CA2356737A1 (en) 2000-07-27
AR022251A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
BR0008182A (pt) Antagonistas do fator de necrose tumoral e seu uso em endometriose
EA200400337A1 (ru) Применение модулятора рецепторов глюкокортикоидов и агониста рецепторов глюкокортикоидов при получении лекарственного средства
BR0308739A (pt) Tratamentos em combinação para doenças mediadas por quimiocina
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
AU2304300A (en) Indole derivatives and their use as mcp-1 receptor antagonists
MA26843A1 (fr) NOUVELLES COMPOSITIONS ESTRO-PROGESTATIVES TOPIQUES à EFFET SYSTÉMIQUE
BR0107683A (pt) Drospirenona para terapia de reposição de hormÈnio
EP1023315A4 (en) METHODS AND PREPARATIONS FOR DESTRUCTING SPECIFIC PROTEINS
BRPI0415971A (pt) método para tratar, prevenir ou controlar degeneração macular, e, composição farmacêutica
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
BRPI0416260A (pt) método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica
NO20100041L (no) Anvendelse av AT-1 reseptorantagonist eller AT-2 reseptormodulator for behandling av sykdommer assosiert med en okning av AT-1 eller AT-2 reseptorer
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
NO20031323L (no) Peptid-baserte forbindelser
BR0208533A (pt) Derivados de sapogenina, sìntese e uso dos mesmos e processos com base em seu uso
CA2360313A1 (en) Glucocorticoid receptor modulators
CR7936A (es) Formulaciones parenterales de un peptido para el tratamiento de lupus sitemico eritematoso
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
ATE334139T1 (de) 17 beta-nitro-11 beta-arylsteroide und deren derivate mit hormonalen agonist- oder antagonisteigenschaften
BR0109515A (pt) Derivados da apomorfina e métodos para seu uso
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
BRPI0410739A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11 E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.